Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The restructuring aims to create synergies across the business and strengthen capital structure
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
His resignation would be effective from March 18, 2024
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The Product will be manufactured at the company's facility in Bengaluru
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Subscribe To Our Newsletter & Stay Updated
